Table 1

Primary antibodies

AntibodyHost/clone/isotypeEpitopeConcentrationSource/reference
αGrabbitα-Gliadin1:10015
GliadinrabbitGliadin1:50Sigma, St Louis, Missouri, USA
WB8m/WB8/IgG1GQQQPFPPQ1:2016
R5m/R5/IgG2aQQQPFP1:2524 25
LAMP-2m/H4B4/IgG1Human LAMP-21:20Pharmingen, San Diego, California, USA
LAMP-1m/BB6Human LAMP-11:10M Fukuda, San Diego, California, USA
LAMP-2m/CD3Human LAMP-21:50M Fukuda, San Diego, California, USA
LAMPrabbitHuman LAMP-1 and -21:10M Fukuda, San Diego, California, USA
Cathepsin DrabbitHuman cathepsin D1:40Dako, Hamburg, Germany
HLA-DR/DP/DQm/CR3/43/IgG1β-Chain1:5J Cordell, Oxford, UK
HLA-DR*m/L243/IgG2aα- and β-Chain, HLA-DR1:5Becton & Dickinson, Heidelberg, Germany
HLA-DQm/SPV-L3/IgG2aα-Chain, HLA-DQ1:5Serotec, Oxford, UK
MHC class IIrabbitα-Chain1:20PJ Peters, Amsterdam, The Netherlands
  • * Biotinylated.

  • WB8 was raised against the gliadin peptide B3144, which comprises the amino acid sequence 3–56 of A-gliadin. For immunofluorescence experiments the primary antibodies were used at up to 10 times higher dilutions as indicated.

  • HLA, human leucocyte antigen; IgG, immunoglobulin G; LAMP, lysosomal-associated membrane protein; m, mouse.